Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Biochimie|June 6, 1998
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncologyG Vassal, C Pondarré, I Boland, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastasesJ N Munck, P Rougier, G G Chabot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humansA Santos, S Zanetta, T Cresteil, et al.
Head & Neck|March 1, 1994
Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissuesO Parise, F Janot, B Luboinski, et al.
Bulletin Du Cancer|January 1, 1990
[Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide (PEC protocol)]D Baume, J L Pico, J P Droz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancerJ P Droz, J L Pico, M Ghosn, et al.
Biochimica Et Biophysica Acta|October 13, 1992
Active metabolism of arachidonic acid by Kaposi sarcoma cells cultured from lung biopsies (KS-3); identification by HPLC and MS/MS of the predominant metabolite secreted as the 11,12-epoxy-eicosatrienoic acidF Dray, B Vulliez-Le Normand, A Deroussent, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Pageof 10